Henner WD - Search Results

1

Cyclophosphamide and thiotepa with autologous bone marrow transplantation in patients with solid tumors.

Eder JP, Antman K, Elias A, Shea TC, Teicher B, Henner WD, Schryber SM, Holden S, Finberg R, Chritchlow J, et al. Eder JP, et al. Among authors: henner wd. J Natl Cancer Inst. 1988 Oct 5;80(15):1221-6. doi: 10.1093/jnci/80.15.1221. J Natl Cancer Inst. 1988. PMID: 3138431

2

Pharmacokinetics of continuous-infusion high-dose thiotepa.

Henner WD, Shea TC, Furlong EA, Flaherty MD, Eder JP, Elias A, Begg C, Antman K. Henner WD, et al. Cancer Treat Rep. 1987 Nov;71(11):1043-7. Cancer Treat Rep. 1987. PMID: 3119200

3

Malignant melanoma. Treatment with high-dose combination alkylating agent chemotherapy and autologous bone marrow support.

Shea TC, Antman KH, Eder JP, Elias A, Peters WP, Schryber S, Henner WD, Schoenfeld DA, Schnipper LE, Frei E 3rd. Shea TC, et al. Among authors: henner wd. Arch Dermatol. 1988 Jun;124(6):878-84. doi: 10.1001/archderm.124.6.878. Arch Dermatol. 1988. PMID: 3288124

4

A phase I clinical and pharmacokinetic study of carboplatin and autologous bone marrow support.

Shea TC, Flaherty M, Elias A, Eder JP, Antman K, Begg C, Schnipper L, Frei E 3rd, Henner WD. Shea TC, et al. Among authors: henner wd. J Clin Oncol. 1989 May;7(5):651-61. doi: 10.1200/JCO.1989.7.5.651. J Clin Oncol. 1989. PMID: 2651580 Clinical Trial.

5

Cross-resistance and glutathione-S-transferase-pi levels among four human melanoma cell lines selected for alkylating agent resistance.

Wang YY, Teicher BA, Shea TC, Holden SA, Rosbe KW, al-Achi A, Henner WD. Wang YY, et al. Among authors: henner wd. Cancer Res. 1989 Nov 15;49(22):6185-92. Cancer Res. 1989. PMID: 2804968

6

Identification of an anionic form of glutathione transferase present in many human tumors and human tumor cell lines.

Shea TC, Kelley SL, Henner WD. Shea TC, et al. Among authors: henner wd. Cancer Res. 1988 Feb 1;48(3):527-33. Cancer Res. 1988. PMID: 3275499

7

High-dose combination alkylating agents with autologous bone marrow support: a Phase 1 trial.

Peters WP, Eder JP, Henner WD, Schryber S, Wilmore D, Finberg R, Schoenfeld D, Bast R, Gargone B, Antman K, et al. Peters WP, et al. Among authors: henner wd. J Clin Oncol. 1986 May;4(5):646-54. doi: 10.1200/JCO.1986.4.5.646. J Clin Oncol. 1986. PMID: 3517240

8

High-dose combination alkylating agent chemotherapy with autologous bone marrow support for metastatic breast cancer.

Eder JP, Antman K, Peters W, Henner WD, Elias A, Shea T, Schryber S, Andersen J, Come S, Schnipper L, et al. Eder JP, et al. Among authors: henner wd. J Clin Oncol. 1986 Nov;4(11):1592-7. doi: 10.1200/JCO.1986.4.11.1592. J Clin Oncol. 1986. PMID: 3534155

9

High-dose combination alkylating agent preparative regimen with autologous bone marrow support: the Dana-Farber Cancer Institute/Beth Israel Hospital experience.

Antman K, Eder JP, Elias A, Shea T, Peters WP, Andersen J, Schryber S, Henner WD, Finberg R, Wilmore D, et al. Antman K, et al. Among authors: henner wd. Cancer Treat Rep. 1987 Feb;71(2):119-25. Cancer Treat Rep. 1987. PMID: 3542208

10

Pharmacokinetics and immediate effects of high-dose carmustine in man.

Henner WD, Peters WP, Eder JP, Antman K, Schnipper L, Frei E 3rd. Henner WD, et al. Cancer Treat Rep. 1986 Jul;70(7):877-80. Cancer Treat Rep. 1986. PMID: 3719578

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

85 results

Search Page

Filters